2019 Cannabis Business Award's
Publication of the Year |
NEXT ZOOM MEETING WILL BE ON WEDNESDAY, JUNE 21, 2023 AT 6:30PM LEGISLATIVE UPDATE
& REVIEW OF FMCCE THE "FLORIDA MEDICAL CANNABIS
PHYSICIAN GROUP" (FMCPG) FOR ALL "MEDICAL MARIJUANA DOCTORS"
AND "MMTC DIRECTORS ONLY "
TOPICS TO BE DISCUSSED UPDATE FROM TALLAHASSEE ON TELEHEALTH BILL FOR CANNABIS PATIENTS PASSED BY THE HOUSE AND SENATE, NOW WAITING FOR THE GOVERNOR
UPDATE FROM TALLAHASSEE ON THE HEMP BILL PROTECTING YOUR MEDICAL CANNABIS PRACTICE QUESTIONS FROM PHYSICIANS
HOW TO BEST ANSWER YOUR PATIENT QUESTIONS |
NEWS FROM THE PAST WEEK
RELATING TO THE BUSINESS OF CANNABIS IN FLORIDA Click on Company Logo to be Transferred to Web Site |
TRULIEVE OPENING NEW DISPENSARY IN PHOENIX, ARIZONA
Opening of Trulieve dispensary on Tatum Blvd. continues brand promise of offering the right products at the right price in the right place in growing Phoenix market
June 13, 2023 — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company in the United States, today announced the opening of a new dispensary in Phoenix, AZ. Located at 16635 N. Tatum Boulevard, the doors will open at 8 AM on Tuesday, June 13, 2023, with ongoing hours of 8 AM to 10 PM seven days a week.
“Trulieve is a proud member of the Arizona community and this new location on Tatum Boulevard is a continuation of our brand promise to deliver exceptional customer experiences, as well as provide the right products at the right price in the right place,” said Kim Rivers, CEO of Trulieve. “This new location will offer a wide variety of popular products including Trulieve brands such as Alchemy, Avenue, Co2lors, loveli, Modern Flower, Muse, and Roll One.”
Trulieve invites the Arizona community to join in celebrating this new recreational marijuana dispensary on Saturday, June 17 with partner giveaways, DJs, a coffee truck, special discounts and more, starting at 8 AM.
READ MORE |
NEW NAME
HOUSE OF PLATINUM CANNABIS |
RED WHITE & BLOOM AND ALEAFIA HEALTH EXECUTE BINDING LETTER AGREEMENT FOR BUSINESS COMBINATION
The Combined Company (as defined below) is expected to represent C$138 million in trailing distribution and retail revenue from the Canadian, United States and European cannabis end-markets and combined Gross Profit before fair value adjustments of $39 million.(1)(2)(3)(4)
On a combined basis, RWB and Aleafia are expected to service approximately 3,000 retail locations in North America. (1)(2)(3)(4)
Expected annualized synergies of approximately C$10 million in COGS and SG&A through optimization and economies of scale, and elimination of debt service obligations. (1)(2)(3)(4)
TORONTO, June 07, 2023 — Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB” or the “Company”) and Aleafia Health Inc. (TSX: AH and OTCQB: ALEAF) (“Aleafia”) are pleased to announce that the Company and Aleafia have entered into a binding letter agreement on June 6, 2023 (the “Letter Agreement”) whereby the Company has agreed to acquire Aleafia and its subsidiaries in a business combination transaction (the “Proposed Transaction”).
READ MORE |
VERANO TO INTRODUCE BEST-IN-CLASS OPERATIONS IN ALABAMA MARKET AFTER WINNING COVETED VERTICAL LICENSE
Organic Vertical License Win Will Expand Company’s National Footprint and Strengthen Strategic Presence in the Southeast
The Alabama vertical license will allow Verano to operate a cultivation and processing facility and five retail cannabis dispensaries throughout the state
The addition of Alabama, a state with a growing population of more than 5 million residents1, will increase Verano’s active operations to 14 states nationwide
Alabama cannabis sales are projected to reach as high as $695 million by 20282
Verano’s current active operations span 13 states, comprised of 129 dispensaries and 14 cultivation and processing facilities with more than 1 million square feet of cultivation capacity
CHICAGO, June 12, 2023 — Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that following a competitive application bid process overseen by the state’s Medical Cannabis Commission, Verano Alabama, LLC, a joint venture established by Verano, has been awarded one of five highly-coveted Integrated Facility Licenses in Alabama. The vertical license will permit Verano Alabama to operate a cultivation and processing facility and five retail cannabis dispensaries throughout the state.
With the addition of Alabama, Verano continues to build its national footprint by bolstering its presence in the Southeast, adding another medical market in the region that complements the Company’s robust vertical Florida operations. Alabama cannabis sales are projected to reach as high as $695 million by 2028.
READ MORE |
NATIONAL AND INTERNATIONAL NEWS |
BDSA FORECASTS LEGAL U.S. CANNABIS MARKET TO REACH $45 BILLION IN 2027
Spotlight on state-level developments: tracking the booming cannabis markets in Missouri, New York and more
LOUISVILLE, Colo., June 07, 2023 (GLOBE NEWSWIRE) — BDSA, the leading provider of market intelligence for the cannabis industry, today released its key market forecast update, revealing the legal United States cannabis market is expected to grow 12% by the end of 2023, reaching $29.6 billion. By 2027, the U.S. is forecast to deliver $45 billion in total legal sales. The total global legal cannabis industry is predicted to reach $36.7 billion in 2023 (with 80% of sales from U.S. markets), growing at a compound annual growth rate (CAGR) of 13% from 2022 to 2027. To continue to provide the most accurate and comprehensive data, BDSA has evolved its Market Forecast release cadence from biannually to quarterly.
“Over the next five years, the biggest drivers of cannabis industry growth in the U.S. will be the thriving Midwest and East Coast markets,” said Roy Bingham, co-founder and CEO of BDSA. “New markets, especially adult-use markets like Missouri, New Jersey and New York, will lead growth. Although mature Western markets such as Colorado and California have experienced sales stagnation or decline due to price compression, they will continue to account for a substantial portion of legal sales through 2027.”
READ MORE |
UNRIVALED BRANDS APPOINTS PATTY CHAN AS PERMANENT CFO, ANNOUNCES MATERNITY LEAVE, AND INTERIM CFO APPOINTMENT
June 13, 2023 — Unrivaled Brands, Inc. (OTCQB: UNRV) (“Unrivaled,” “Unrivaled Brands,” or the “Company”), a cannabis company with operations throughout California, today announced that its Interim Chief Financial Officer (“CFO”’), Patty Chan, has been appointed as the Company’s permanent CFO. Patty Chan has served as the Company’s Interim CFO since September 12, 2022, bringing a wealth of experience and grit, and contributing significantly to Unrivaled’s financial progress. The Board is thrilled to make Patty’s position permanent and continues to be confident in her strategic direction and financial oversight at Unrivaled. Ms. Chan will be taking maternity leave starting June 26, 2023 and is expected to return to her role by November 1, 2023.
READ MORE |
USFDA APPROVES LANEO MDMA FOR CLINICAL TRIAL USE IN THE UNITED STATES
Approved Study to Examine Tolerability of MDMA in Schizophrenia at UCLA
VANCOUVER, British Columbia, June 09, 2023 – PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA)(OTC:PMBHF), a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules (including MDMA), is pleased to report that the US Food and Drug Administration (USFDA) has approved a clinical trial utilizing PharmAla’s LaNeo MDMA Investigational Medical Product (IMP) capsules (40mg). This is the first time that PharmAla’s IMP has been approved for trial use in the United States.
“While we’ve had great success with many regulators around the world, it’s still a major milestone to receive a stamp of approval from USFDA for our investigational drugs,” said Dr. Harpreet Kaur, Vice President of Research at PharmAla Biotech. “As with any IMP supplier, there are always questions about Chemistry, Manufacturing and Control – even for well-known molecules. We believe that this announcement should confirm that our IMP conforms to the high levels of quality and documentation that one of the preeminent regulators in the world requires.
READ MORE |
HEMPSANA HOLDINGS LTD. (THE “CORPORATION” OR “HEMPSANA”) ANNOUNCES RESTRUCTURED FINANCING
June 12, 2023 — Hempsana (CSE: HMPS) announced today that it has entered into an agreement to restructure the previously announced investment in the Corporation by Antosh Consulting Inc. (the “Investor”) into an equity issuance, following consultation with the Canadian Securities Exchange (the “CSE”). Hempsana previously had entered into a Convertible Debt Purchase Agreement (the “Initial Agreement”) with the intent to borrow an aggregate principal amount of $900,000 pursuant to an unsecured convertible debenture (the “Debenture”). The Initial Agreement was entered into on May 11, 2023, however the Debenture was never issued to the Investor and no securities were issued pursuant to either the Initial Agreement or the Debenture.
In lieu of proceeding with the Initial Agreement, Hempsana and the Investor have entered into a Subscription Agreement for Units of Hempsana (the “Subscription Agreement”), pursuant to which the Investor has agreed to purchase 30,000,000 Units of the Corporation (each, a “Unit”) at a price of $0.03 per Unit, for a total purchase price of $900,000.00 (the “Subscription Price”), by way of a private placement exemption from the prospectus requirement. Each Unit is comprised of one Common Share and one-sixth of one Common Share purchase warrant in the capital of Hempsana (each whole such warrant, a “Warrant”). The Unit offering is expected to close on or about June 12, 2023.
READ MORE |
RESEARCH FINDINGS ON ART12.11 AT THE 33RD ANNUAL INTERNATIONAL CANNABINOID RESEARCH SOCIETY SYMPOSIUM
ART12.11, a Novel and Patented Cocrystal of Cannabidiol, Improves Bioavailability and Efficacy of CBD
SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it was selected for an oral presentation at the 33rd International Cannabinoid Research Society (ICRS) Symposium being held on June 24-29, 2023 in Toronto, Ontario, Canada, at the Marriott Downtown at CF Toronto Eaton Centre.
Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, is scheduled to present new data on ART12.11, Artelo’s patented cannabidiol cocrystal, at the ICRS on Sunday, June 25th at 9:15 EDT. Results from preclinical studies with ART12.11 in stress-induced anxiety and depression that were conducted at the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada, will be presented by Professor O’Sullivan as well as data related to ART12.11’s pharmacokinetics as compared to other forms of CBD.
READ MORE |
LIFEIST’S CANNMART SUCCESSFULLY LAUNCHES MULTI-PACK CONCENTRATES IN BRITISH COLUMBIA
CannMart’s In-house brand Roilty sells-out all stock from initial purchase order of multi-pack cannabis concentrate in British Columbia
TORONTO, June 08, 2023 — Lifeist Wellness Inc. (“Lifeist” or the “Company”) (TSXV: LFST) (FRANKFURT: M5B) (OTCMKTS: LFSWF), a health-tech company that leverages advancements in science and technology to build breakthrough companies that transform human wellness, is pleased to announce the highly successful launch of its premium multi-pack cannabis concentrate offerings in British Columbia through its Canadian cannabis business unit, CannMart Inc. (“CannMart”). The introduction of Roilty Shatter multipacks in April resulted in exceptional sales, with over 3,000 units sold.
“Our successful launch in British Columbia further solidifies Roilty’s trajectory of robust growth, building upon its accomplishments in Ontario, Canada’s largest provincial cannabis market,” said Daniel Stern, CEO of CannMart. “Discerning consumers in BC highly value the convenience and value proposition of Roilty’s multi-packs. Renowned for its exceptional quality and dedication to crafting top-notch concentrates, Roilty has garnered significant recognition. The strong reception and demand for Roilty’s multi-pack offerings are a testament to our ability to meet consumer preferences and drive growth within the cannabis market. The early accomplishment in BC paves the way for future expansions and the introduction of exciting products in other regions.”
READ MORE |
ATLAS GLOBAL BRANDS PROVIDES CORPORATE UPDATE AND OUTLINES GROWTH STRATEGY
Strong execution since going public on the Canadian Securities Exchange (the “CSE”) in January 2023
Atlas launches D*gg Lbs brand in collaboration with Snoop Dogg, first SKUs ready for OCS summer product call
Solidifying integrated value chain with Canadian cultivation facilities and Israeli acquisitions
Streamlining operations and leveraging existing value chain capabilities
Atlas will host an investor webinar on June 22 at 8 AM PT/ 11 AM ET
CHATHAM, ONTARIO and TEL-AVIV, ISRAEL, June 07, 2023 — Atlas Global Brands Inc. (“Atlas Global”, “Atlas” or the “Company”) (CSE: ATL), a cannabis company with expertise across the value chain, is pleased to provide an update on the Company’s recent milestones, business integration activities and global growth catalysts. Atlas will also host a webinar on June 22, 2023, to provide an overview of the Company and its strategic objectives ahead. Investors can register to attend here. A recording of the webinar will be made available on Atlas’ investor relations website.
READ MORE |
MARIMED ANNOUNCES THRIVE WELLNESS DISPENSARY OPENING TIFFIN, OHIO
June 12, 2023 – MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced it opened a Thrive Wellness Dispensary medical dispensary in Tiffin, Ohio, marking the Company’s first operational dispensary in the state and the 11th that MariMed owns or manages across five states. The dispensary, the first in Seneca County, a western Ohio county with 54,000 residents, is located at 318 W. Market Street.
READ MORE |
BELOW ARE THE LINKS TO THE DIRECTORY OF FLORIDA CANNABIS DOCTORS AND
DISPENSARIES IN THE STATE OF FLORIDA |
QUALIFIED PATIENTS OVER 825,000 AND 574 DISPENSING LOCATIONS
|
LATEST OMMU REPORTS FROM OFFICE OF MEDICAL MARIJUANA USE IN THE STATE OF FLORIDA Highlights from
JUNE 9, 2023
Report BY THE NUMBERS
Qualified Patients: (Active ID Card): JUN 09 2023- 825,109
JUN 02 2023- 822,818 MAY 26 2023- 820,823 MAY 19 2023- 818,679
MAY 12 2023- 816,944
Patients Last Week: 2,291 Qualified Ordering Physicians: 2,494 New Doctors Last Week: 14 Reporting Period: JUNE 2 TO JUNE 8 2023
Amount of Medical Marijuana Dispensed - (mgs THC) 398,639,633 Amount of Low-THC Cannabis Dispensed - (mgs CBD) 3,067,885 Amount of Marijuana in a From for Smoking (oz) 103,841.527 Approved Dispensing Locations: 568 ADD LAST WEEK +3
GREEN DRAGON - INVERNESS INSA - JACKSONVILLE
SUNNYSIDE - DESTIN |
UPCOMING MEETING AND CONFERENCES |
ADVERTISEMENT OPPORTUNITIES
If your goal is to get your business in front of the right people in the cannabis industry or you want to be an integral part of this new and exciting business opportunity, then you need to join with Cannabis News Florida as we help to establish cannabis as a major part of the economy in Florida. Cannabis News Florida is an online publication focusing on both local and national news from leading authorities about the medical and business developments in the medical cannabis industry covering the entire state of Florida.
Join the Cannabis News Florida force online and in print. We offer several marketing options to fit all budgets:
· MMTC PROMOS LISTED IN EACH E-NEWSLETTER
• Directory Listing
• Banner Ads
• Ad Space in the Newspaper
• Feature Articles
• Weekly Newsletters
For further information or to make your ad reservation, please call:561-368-6950 / 954-605-4785 cell charles@cannabisnewsflorida.com
|
|
|